2.78
Inmune Bio Inc Aktie (INMB) Neueste Nachrichten
What analysts say about INmune Bio Inc. stockOutstanding yields - PrintWeekIndia
Is INmune Bio Inc. a good long term investmentOutstanding capital growth - PrintWeekIndia
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference - The Manila Times
INmune Bio to present additional Phase 2 Alzheimer’s trial data - Investing.com Australia
When (INMB) Moves Investors should Listen - news.stocktradersdaily.com
INmune Bio Inc. Stock Analysis and ForecastHigh-yield trading alerts - jammulinksnews.com
What drives INmune Bio Inc. stock priceRapid wealth accumulation - jammulinksnews.com
Is INmune Bio Inc. stock overhyped or has real potentialFree Stock Selection with 300% Return - Newser
Why INmune Bio Inc. stock attracts strong analyst attentionInsider Strategy Insight - Newser
How INmune Bio Inc. stock performs during market volatilityCapital Growth Picks - Newser
Cambridge Investment Research Advisors Inc. Makes New $180,000 Investment in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
What makes INmune Bio Inc. stock price move sharplyTop Momentum Stock Pick - Newser
INmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug Trial - MSN
Where are the Opportunities in (INMB) - news.stocktradersdaily.com
INmune Bio shares slide after Phase II Alzheimer’s trial misses endpoints - MSN
INmune Bio reverses early gains after stock offering - MSN
INmune Bio surges ahead of mid-stage trial readout for Alzheimer’s drug - MSN
INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low - MSN
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Benzinga
INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble - MSN
XPro™'s Subgroup Success: A Silver Lining in INmune Bio's Alzheimer's Setback - AInvest
INmune Bio's $19M Funding: A Lifeline or a Launchpad for Breakthroughs? - AInvest
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
(INMB) Proactive Strategies - news.stocktradersdaily.com
INmune Bio Shares Fall After Downgrade From BTIG Research - MarketScreener
INmune Bio Shares Plunge After Alzheimer's Trial Misses Target - Finimize
INmune Bio (INMB) Faces Significant Downgrade by Scotiabank | INMB Stock News - GuruFocus
A Drug-Trial Stock Sale - Bloomberg.com
INmune Bio stock downgraded by Raymond James after Alzheimer’s trial miss - Investing.com Australia
Inmune Bio Secures $18.9 Million in Stock Offering - TipRanks
Clinical-Stage Biotech INmune Bio Secures $19M Through Strategic Share Offering - Stock Titan
Raymond James Downgrades INmune Bio to Market Perform From Outperform; Shares Fall - MarketScreener
Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s - TipRanks
INmune Bio shares tumble as Alzheimer’s drug falls short in mid-stage trial - Proactive Investors
INmune Bio's XPro: A Missed Milestone or a Hidden Gem in Alzheimer's Drug Development? - AInvest
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial By Stocktwits - Investing.com India
INmune Bio’s Stock Tanks: Worth Considering? - timothysykes.com
INmune Bio’s Alzheimer’s drug shows benefit in inflammatory subset - Investing.com
INmune Bio’s Alzheimer’s drug shows benefit in inflammatory subset By Investing.com - Investing.com UK
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease - The Manila Times
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):